Hematopoietic stem cells represent the molecular wellspring from which the entire blood system arises, responsible for lifelong production of diverse blood lineages. However, the function and regenerative potential of HSCs decline with age, impairing immune competence and tissue renewal. What epigenetic changes drive this deterioration? By employing high-resolution epigenetic profiling technologies, the authors unravel how age-associated modifications to DNA methylation and chromatin accessibility reshape the transcriptomic networks that define HSC functionality. This extensive profiling in male murine models is among the most detailed to date, offering novel insights with possible human translational relevance.

Central to this research are the transcriptional regulators KDR (kinase insert domain receptor, also recognized as VEGFR2) and PU.1 (SPI1), both known for their involvement in hematopoietic development but now highlighted for their regulatory influence over age-associated transcriptional trajectories. KDR, traditionally studied in endothelial cell biology and angiogenesis, emerges here as a significant modulator of the aged HSC epigenome. PU.1, a master regulator of myeloid and lymphoid differentiation, similarly assumes a critical role in governing how the aging HSC transcriptome adapts both intrinsically and in response to extrinsic stimuli such as caloric restriction.

Caloric restriction (CR) stands as one of the most robust phenotypic interventions shown to extend lifespan and delay age-related decline across multiple species. Yet, the molecular intermediaries through which CR impacts stem cell aging have remained elusive. This study meticulously documents how CR influences the epigenetic states mediated by KDR and PU.1, indicating that these factors serve as molecular conduits translating metabolic cues into enduring alterations of gene expression programs. These findings bridge a significant knowledge gap by unveiling mechanistic links between diet, epigenetics, and stem cell aging.

Cutting-edge single-cell multi-omics approaches were harnessed to dissect how aging reconfigures chromatin landscapes across individual HSCs, revealing heterogeneity in responses that would be masked in bulk analyses. The investigators observed that age precipitates a progressive shift toward a repressive chromatin state, constraining the accessibility of genes crucial for stem cell maintenance and lineage commitment. Intriguingly, CR was shown to counteract some of these alterations, sustaining a more ‘youthful’ epigenomic architecture, which correlated with improved hematopoietic function. KDR and PU.1 motif enrichments were enriched in genomic loci whose accessibility was preserved with CR, indicating their central role.

The study also pioneers a systems biology perspective by integrating epigenetic profiling data with transcriptomic outputs to map the gene regulatory networks (GRNs) underpinning HSC aging. This reveals that the interplay between KDR and PU.1 forms a novel regulatory axis critical to maintaining HSC identity and plasticity during aging. Perturbation of this axis in ex vivo cultures altered the expression of key aging-associated genes, highlighting potential therapeutic targets to ameliorate aging phenotypes or rejuvenate aged stem cells.

An unexpected yet compelling aspect of this research is the demonstration of sex-specific epigenetic responses. Although the primary focus was on male mice, these findings open avenues for comparative analyses in females, where hormonal and epigenetic landscapes differ substantially. Understanding gender-specific differences will be crucial for designing personalized anti-aging interventions and ensuring that therapeutic strategies based on epigenetic regulation are broadly efficacious.

Moreover, the elucidation of the dynamic crosstalk between metabolism, epigenetics, and stem cell function exemplifies an integrative biological framework for aging. Metabolic states, modulated by nutritional interventions like CR, influence epigenetic enzymes such as DNA methyltransferases and histone-modifying complexes, which in turn regulate gene expression with lasting consequences on stem cell health. Unpacking this complexity underscores how lifestyle and cellular physiology are intertwined at the molecular level.

This research holds immense translational potential. Targeting the KDR–PU.1 regulatory axis could yield novel agents capable of mimicking caloric restriction’s beneficial effects without requiring drastic dietary changes. Such epigenetic therapeutics might restore youthful gene expression programs, enhance immune regeneration, and delay hematopoietic decline, ultimately improving health-span and resilience in aging populations. The identification of specific epigenetic markers governing stem cell aging also provides invaluable biomarkers for monitoring biological age and treatment efficacy.

The study’s methodology sets new standards for thoroughness and precision in aging research. Using state-of-the-art chromatin immunoprecipitation followed by sequencing (ChIP-seq), combined with assay for transposase-accessible chromatin using sequencing (ATAC-seq) and single-cell RNA sequencing (scRNA-seq), the authors assembled a comprehensive atlas of epigenomic and transcriptomic changes at unparalleled resolution. This multi-dimensional dataset will serve as a vital resource for researchers aiming to decipher aging mechanisms or develop rejuvenative strategies.

Furthermore, the role of PU.1 as a mediator of inflammatory signaling pathways links the aging hematopoietic system to age-related inflammation and immunosenescence, two phenomena at the heart of many chronic diseases. The modulation of PU.1 activity by caloric restriction highlights how environmental and metabolic cues can recalibrate immune cell function, potentially reducing the burden of inflammation-related pathology in the elderly.

While the study addresses important knowledge gaps, it also raises new questions about the reversibility of epigenetic aging marks and the long-term consequences of modulating KDR and PU.1 activities in vivo. Future research will need to explore whether these findings in mice translate to human HSCs, given species-specific nuances in gene regulation and metabolism. Additionally, investigations into the interplay between these factors and other aging hallmarks—such as telomere attrition, proteostasis, and cellular senescence—will complement and expand the current model.

The impact of this work extends beyond hematopoiesis. Since KDR and PU.1 are involved in broader cellular processes, their regulation could affect multiple tissues and organ systems undergoing age-dependent decline. Understanding how systemic factors like CR influence stem cell niches through epigenetic remodeling can pave the way for integrated anti-aging therapies targeting multiple cell types simultaneously.

In conclusion, Zong and colleagues have charted a new frontier in aging research by uncovering a complex epigenetic network with KDR and PU.1 at its core that governs hematopoietic stem cell aging and response to caloric restriction. Their findings not only deepen our comprehension of stem cell biology and aging but also illuminate promising pathways for developing interventions to prolong health-span and combat age-related diseases. As the quest to decode the molecular language of aging continues, this study stands as a milestone illustrating how epigenetics interfaces with metabolism to shape cellular destiny.

Subject of Research: Epigenetic regulation of hematopoietic stem cells aging and response to caloric restriction in male mice.

Article Title: Epigenetic profiling of hematopoietic stem cells from male mice identifies KDR and PU.1 as regulators of aging transcriptome and caloric restriction response.

Article References: Zong, L., Park, B., Tekin-Turhan, F. et al. Epigenetic profiling of hematopoietic stem cells from male mice identifies KDR and PU.1 as regulators of aging transcriptome and caloric restriction response. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69718-0

Image Credits: AI Generated

At the heart of this discovery lies Lamin A/C, known predominantly for its role in maintaining nuclear integrity and chromatin organization. However, this study transcends the classical view by linking Lamin A/C to metabolic fluxes, particularly those involving cysteine, an amino acid pivotal to cellular redox homeostasis and epigenetic regulation. The team meticulously traced how Lamin A/C orchestrates cysteine breakdown pathways, effectively tuning the intracellular metabolite landscape that interfaces with the epigenetic machinery controlling gene expression.

The revelation that cysteine catabolism is not merely a metabolic sidetrack but a critical regulator of stem cell identity underscores the complex connectivity between metabolism and epigenetics. Cysteine-derived metabolites, the study demonstrates, serve as substrates or cofactors for chromatin-modifying enzymes, thus influencing patterns of histone modification and DNA methylation. These epigenetic marks are central determinants in stem cell fate, dictating the silencing or activation of developmental programs.

Delving deeper, the researchers deployed a combination of advanced metabolomics, chromatin immunoprecipitation sequencing (ChIP-seq), and single-cell transcriptomics to elucidate the molecular cascade from Lamin A/C regulation, through cysteine metabolic flux, to epigenomic reconfiguration. The data revealed that alterations in Lamin A/C levels modulate cysteine catabolism flux, which in turn affects the availability of key metabolites required by epigenetic writers such as histone demethylases and DNA methyltransferases.

This mechanism operates as a finely tuned sensor system, wherein Lamin A/C status can relay environmental and cellular cues to the epigenome through metabolic intermediates. Consequently, stem cells leverage this circuitry to dynamically adjust their gene expression profiles in response to physiological demands, striking a balance between self-renewal and differentiation. Such insights deepen understanding of how nuclear architecture can integrate with metabolic networks to govern fundamental biological processes.

The study also highlights how disruption of this Lamin A/C-cysteine axis impacts stem cell function. Loss or mutation of Lamin A/C perturbed cysteine catabolic flux, resulting in aberrant epigenetic landscapes that compromised stem cell pluripotency and biased differentiation trajectories. This finding links nuclear envelope defects observed in laminopathies and aging to metabolic and epigenetic dysregulation, potentially explaining some aspects of stem cell decline observed during aging and disease.

Moreover, by employing pharmacological modulation of cysteine metabolism, the research team demonstrated the capacity to restore proper epigenomic regulation and rescue stem cell function in Lamin A/C-deficient models. This not only validates the causative role of cysteine catabolic flux in maintaining cellular identity but also suggests new metabolic intervention strategies aimed at rejuvenating stem cell pools in degenerative conditions.

Intriguingly, this study provides an integrative model that connects structural nuclear proteins to metabolic pathways and epigenetic control, highlighting an underappreciated axis of cellular regulation. By revealing cysteine catabolism as a key metabolic node influenced by Lamin A/C, the work challenges the canonical compartmentalization of nuclear scaffolding and metabolism as discrete entities, instead proposing a complex, interdependent network maintaining cellular homeostasis.

Technically, the work leveraged state-of-the-art isotope tracing methodologies to precisely quantify flux through cysteine degradation pathways, combined with high-resolution epigenomic profiling to map genome-wide modifications associated with metabolic shifts. The convergence of these approaches allowed for a mechanistic dissection of how metabolic flux imprints on the chromatin landscape, an advancement poised to propel the field of metabolic-epigenetic crosstalk forward.

The implications of these findings are vast, extending beyond fundamental stem cell biology into broader aspects of developmental biology, tissue regeneration, and aging. Understanding how Lamin A/C-mediated metabolic flux modulates the epigenome may help decode the molecular basis for stem cell exhaustion in aged tissues, offering targets to prevent or reverse decline. Furthermore, manipulating this pathway could enhance the efficacy of stem cell-based therapies by stabilizing desirable cell states.

This research also opens new inquiries regarding the possible involvement of other nuclear lamina components and metabolic pathways in epigenetic regulation, potentially revealing a wider network of nuclear-metabolic integration. The bidirectional communication between nuclear structure and metabolism could thus constitute a central axis in cellular function, with broad relevance across cell types and disease contexts.

In summary, the discovery that Lamin A/C controls cysteine catabolic flux to dictate stem cell fate through epigenetic reprogramming represents a landmark advance. It underscores the sophistication of intracellular regulation mechanisms where nuclear architecture, metabolism, and epigenetics intersect seamlessly. Such multidimensional control systems exemplify nature’s complexity and promise new biomedical breakthroughs.

Wang and colleagues’ study delineates a compelling narrative where a structural nuclear protein exerts remarkable influence over cell fate by leveraging metabolic pathways to sculpt the epigenome. This integrative understanding transforms how researchers view nuclear functions and highlights metabolism’s critical role in shaping cell identity beyond traditional bioenergetics.

As this pioneering research paves the way for new therapeutic strategies, it invites the scientific community to expand explorations of epigenome-metabolism interface. Future investigations will likely focus on how modulating this axis in various stem cell types and tissues can optimize regenerative outcomes and combat age-associated decline and disease.

The work stands as a testament to the power of interdisciplinary research blending cell biology, metabolism, and epigenetics. It reveals a nuanced cellular choreography ensuring fundamental decisions on stem cell fate are finely calibrated, unlocking potential to manipulate these processes for improved health and longevity.

In the vibrant landscape of stem cell biology, wherein countless factors converge to determine destiny, this study carves out a novel metabolic-epigenetic niche governed by nuclear lamin dynamics. It challenges existing dogma and sets the stage for a new era of understanding cellular identity control with far-reaching translational impact.

Subject of Research: Stem cell fate regulation through Lamin A/C-controlled cysteine metabolism and epigenome reprogramming

Article Title: Lamin A/C-regulated cysteine catabolic flux modulates stem cell fate through epigenome reprogramming

Article References:
Wang, Y., Shi, H., Wittig, J. et al. Lamin A/C-regulated cysteine catabolic flux modulates stem cell fate through epigenome reprogramming. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01443-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01443-2

Aging represents a multifaceted biological phenomenon characterized by cumulative cellular damage, systemic inflammation, and progressive functional decline across tissues and organ systems. The Parris Longevity Accelerator seeks to harness cutting-edge biotechnologies including artificial intelligence-driven data analytics and high-throughput omics platforms to identify novel diagnostic signatures that herald the onset of debilitating conditions such as osteoarthritis, cardiovascular pathologies, and neurodegenerative diseases. By decoding these biomarkers, the team aims to curate precise and targeted therapies capable of arresting or reversing the trajectory of aging-associated dysfunction before irreversible damage ensues.

At the helm of this Herculean endeavor is Dr. Evseenko, whose expertise navigates the complex terrain of regenerative medicine where stem cell therapeutics intersect with bioengineering solutions. His collaborative synergy with R. Rex Parris, a prominent figure in public service and law, represents nearly a decade-long partnership committed to accelerating translation from bench to bedside. Their shared vision catalyzed the conceptual genesis of the Longevity Accelerator as a dedicated platform for interdisciplinary innovation, marrying scientific discovery with pragmatic clinical applications.

Current demographic trends underscore the urgency of this initiative: approximately four million Americans reach the age of 65 each year, amplifying the societal burden of age-associated chronic diseases. Conventional healthcare models are ill-equipped to mitigate the escalating costs and diminishing quality of life accompanying these conditions. The Longevity Accelerator aspires to remedy this by fostering a research ecosystem that prioritizes rapid generation of therapeutic candidates and streamlines regulatory pathways, thereby compressing the timeline from discovery to clinical implementation.

Central to the Accelerator’s methodology is the integration of artificial intelligence algorithms with large-scale datasets derived from genomics, proteomics, and metabolomics studies. These tools enable unprecedented resolution and predictive accuracy in identifying individuals at elevated risk. Additionally, the deployment of machine learning models facilitates dynamic assessment of disease progression and treatment responsiveness, thereby informing personalized medicine strategies that maximize efficacy while minimizing adverse effects.

The research initiative will initially concentrate on chronic inflammation, a pathological state underlying many age-related morbidities including osteoarthritis and pulmonary diseases. Chronic inflammation disrupts tissue homeostasis and precipitates degenerative processes, positioning it as a critical target for intervention. Building upon pre-existing successes in translating lab-based findings into viable drug development pipelines, Dr. Evseenko’s team is poised to develop novel anti-inflammatory and regenerative therapeutics that aim to restore function and decelerate disease progression.

Another pillar of the project is the inclusion of regulatory science experts who will navigate the complex FDA approval landscape. Their involvement will streamline innovative trial designs and expedite regulatory clearances, ensuring that promising therapies reach patients without unnecessary delays. This multidisciplinary approach underscores the Accelerator’s commitment not only to scientific rigor but also to pragmatic, patient-centered outcomes.

Mayor R. Rex Parris’s philanthropic leadership reflects a profound commitment to addressing the looming healthcare crisis posed by an aging population. His motivation, articulated candidly as a personal fear of mortality, fuels a broader societal imperative: enhancing the quality and duration of life through science and innovation. By partnering with USC’s eminent biomedical researchers, he envisions a future where age-related decline is not an inevitability but a manageable condition.

From the scientific perspective, extending healthspan involves complex biological interventions aimed at sustaining mobility, neuromuscular strength, cognitive function, and cardiovascular health well into advanced age. Achieving this requires unraveling intricate molecular pathways that govern cellular senescence, extracellular matrix remodeling, and neuroimmune interactions. The Longevity Accelerator’s approach to dissecting these pathways represents a paradigm shift from symptom management to disease modification.

The role of regenerative medicine in this context cannot be overstated. Tissue engineering, stem cell therapies, and bioactive scaffolds present unprecedented avenues to repair or replace damaged tissues. Dr. Evseenko’s background uniquely positions him to spearhead approaches that reprogram aged cells, enhance endogenous repair mechanisms, and reestablish homeostatic balance. Such therapies could revolutionize treatment paradigms for osteoarthritis and neurodegenerative disorders, conditions for which current interventions offer only palliative relief.

Technological innovation is further bolstered by advanced imaging modalities and biomaterial design, enabling precise monitoring and modulation of tissue microenvironments. These tools complement molecular assays, facilitating real-time assessment of therapeutic efficacy. Integrating these modalities within the Accelerator’s research pipeline promises accelerated validation and refinement of candidate therapies.

The USC Parris Longevity Accelerator emerges as a beacon of hope amid escalating population aging challenges and healthcare financial strain. By converging expertise across bioengineering, clinical medicine, data science, and regulatory affairs, this initiative exemplifies a holistic strategy to combat the biological ravages of time. As the project unfolds, it holds transformative potential not only for millions of Americans but also as a blueprint for global efforts to promote healthy aging.

Steven D. Shapiro, USC’s Senior Vice President for Health Affairs, encapsulates the initiative’s promise: the Accelerator will be a catalyst for breakthrough discoveries that enhance human health throughout life’s continuum. Jay R. Lieberman, MD, chair of the orthopedic surgery department at Keck, highlights this endeavor as medicine’s next frontier, one poised to fundamentally shift our approach to aging from inevitability to intervention.

With an unprecedented infusion of resources, visionary leadership, and multidisciplinary expertise, the USC Parris Longevity Accelerator stands at the vanguard of a new era in biomedical research. Its impact promises to resonate far beyond academia, heralding a future where longevity and vitality extend hand in hand.

—

Subject of Research: Longevity research focusing on aging, regenerative medicine, and early interventions for age-related diseases including osteoarthritis, cardiovascular, and neurodegenerative disorders.

Image Credits: Photo/Jeremi Peck

Keywords: Aging populations, Arthritis, Osteoarthritis, Cardiovascular disorders, Neurodegenerative diseases, Chronic inflammation, Gerontology, Regenerative medicine